# Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis

> **NCT00175045** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 68 (actual)

## Conditions studied

- Esophagitis
- Reflux

## Interventions

- **DRUG:** Lansoprazole
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT00175045
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2010-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00175045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00175045, "Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00175045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*